Galderma Group AG (XSWX:GALD) 5-Year EBITDA Growth Rate: 0.00% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:GALD Galderma Group AG XSWX:GALD
15 GF Score
Price CHF175.75
! 3 Warning Signs
View Full Analysis

What is Galderma Group AG 5-Year EBITDA Growth Rate?

Galderma Group AG XSWX:GALD -2.71% 15 5-Year EBITDA Growth Rate is 0.00% as of Jun. 2026. GuruFocus rates XSWX:GALD with a GF Score™ of 15/100. The stock has 3 warning signs investors should review.

Galderma Group AG's EBITDA per Share for the six months ended in Jun. 2026 was CHF2.71.

During the past 12 months, Galderma Group AG's average EBITDA Per Share Growth Rate was 33.60% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 16.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 5 years, the highest 3-Year average EBITDA Per Share Growth Rate of Galderma Group AG was 20.80% per year. The lowest was 16.00% per year. And the median was 18.40% per year.

Galderma Group AG  (XSWX:GALD) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Galderma Group AG 5-Year EBITDA Growth Rate Related Terms

XSWX:GALD vs ZTS, UTHR, VTRS: 5-Year EBITDA Growth Rate Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Galderma Group AG's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Galderma Group AG 5-Year EBITDA Growth Rate vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Galderma Group AG's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Galderma Group AG's 5-Year EBITDA Growth Rate falls into.


XSWX:GALD
15GF Score
Galderma Group AG XSWX:GALD
5-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Galderma Group AG 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 5-Year EBITDA Growth Rate of 0.00% mean?
Galderma Group AG (XSWX:GALD) has a 5-Year EBITDA Growth Rate of 0.00% as of Jun. 2026. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Galderma Group AG and its competitors.
Is Galderma Group AG's 5-Year EBITDA Growth Rate too high?
Galderma Group AG's current 5-Year EBITDA Growth Rate is 0.00%. Overall, Galderma Group AG has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Galderma Group AG's 5-Year EBITDA Growth Rate compare to ZTS and UTHR?
Galderma Group AG's 5-Year EBITDA Growth Rate of 0.00% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Drug Manufacturers company?
A good 5-Year EBITDA Growth Rate depends on the Drug Manufacturers industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Galderma Group AG and its competitors. Galderma Group AG's current 5-Year EBITDA Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Galderma Group AG stock overvalued right now?
Galderma Group AG (XSWX:GALD) has a current 5-Year EBITDA Growth Rate of 0.00%. The current 5-Year EBITDA Growth Rate is 0.00%. Galderma Group AG's overall GF Score™ is 15/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For Galderma Group AG (XSWX:GALD), the current 5-Year EBITDA Growth Rate is 0.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Galderma Group AG Business Description

Address Zahlerweg 10, Zug, CHE, 6300
Galderma was formed in 1981 as a joint venture between Nestle and L'Oreal. It subsequently became a subsidiary of Nestle, called Nestle Skin Health, before being carved out and launched as a stand-alone company in 2019, acquired by a consortium led by Sweden-based EQT fund. The company went public in March 2024 and is listed on the SIX Swiss exchange. Galderma's science-based portfolio spans multiple dermatology categories, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. It derives around 40% of net sales from the US and employs more than 7,500 people.
15GF Score

Get the complete analysis for XSWX:GALD

5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF175.75
Price